US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US20030109503A1
(en)
*
|
1995-06-06 |
2003-06-12 |
Smithkline Beecham P.L.C. |
Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
ES2248908T7
(es)
|
1997-06-06 |
2014-11-24 |
Depomed, Inc. |
Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
|
ID26082A
(id)
|
1998-03-19 |
2000-11-23 |
Briston Myers Squib Company |
Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
US7250176B1
(en)
*
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
US6586438B2
(en)
*
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
ES2270982T3
(es)
|
2000-02-04 |
2007-04-16 |
Depomed, Inc. |
Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
|
US6544555B2
(en)
*
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
KR20030047873A
(ko)
*
|
2000-02-29 |
2003-06-18 |
테바 파마슈티컬 인더스트리즈 리미티드 |
클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
|
EP1267840B1
(de)
*
|
2000-03-28 |
2009-06-03 |
Sandoz AG |
Geschmackmaskierte granulierte teilchen
|
US6488962B1
(en)
*
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
US7527807B2
(en)
|
2000-06-21 |
2009-05-05 |
Cubist Pharmaceuticals, Inc. |
Compositions and methods for increasing the oral absorption of antimicrobials
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
BR0114272A
(pt)
*
|
2000-09-29 |
2003-08-26 |
Solvay Pharm Bv |
Formulação farmacêutica de liberação prolongada independente da força iÈnica
|
EP1322158B1
(de)
*
|
2000-10-02 |
2012-08-08 |
USV Ltd. |
Metformin enthaltende pharmazeutische Zusammensetzungen mit verzögerter Wirkstofffreigabe und Verfahren zu deren Herstellung
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
EP1330236A2
(de)
|
2000-10-12 |
2003-07-30 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillinhaltige arzneizusammensetzungen
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
FR2816840B1
(fr)
|
2000-11-17 |
2004-04-09 |
Flamel Tech Sa |
Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
CZ20033211A3
(cs)
*
|
2001-05-03 |
2004-09-15 |
F. Hoffmann-La Roche Ag |
Farmaceutická léková forma amorfního nelfinavir mesylátu
|
US20030031711A1
(en)
*
|
2001-05-29 |
2003-02-13 |
Fara John W. |
Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
|
US6524618B1
(en)
*
|
2001-06-12 |
2003-02-25 |
Vijai Kumar |
Directly compressible extended-release matrix formulation for metformin hydrochloride
|
WO2003004009A1
(en)
*
|
2001-07-02 |
2003-01-16 |
Geneva Pharmaceuticals, Inc. |
Pharmaceutical composition
|
CA2452738C
(en)
*
|
2001-07-04 |
2011-06-14 |
Sun Pharmaceutical Industries Limited |
Gastric retention controlled drug delivery system
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
EP2311460A1
(de)
*
|
2001-07-06 |
2011-04-20 |
Endo Pharmaceuticals Inc. |
Kontrolliert freisetzende Formulierungen von Oxymorphon
|
EP1404331B1
(de)
*
|
2001-07-06 |
2007-10-31 |
Penwest Pharmaceuticals Co. |
Verzögert freisetzende formulierungen von oxymorphon
|
ITMI20011457A1
(it)
*
|
2001-07-09 |
2003-01-09 |
Valpharma Sa |
Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
|
US20040219186A1
(en)
*
|
2001-08-16 |
2004-11-04 |
Ayres James W. |
Expandable gastric retention device
|
CA2459976A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
PE20030527A1
(es)
*
|
2001-10-24 |
2003-07-26 |
Gruenenthal Chemie |
Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
US6723340B2
(en)
*
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
AU2002351798A1
(en)
*
|
2001-10-29 |
2003-05-12 |
Labopharm Inc. |
Methods and dosage forms for improving the bioavailability of therapeutic agents
|
CN1700910A
(zh)
*
|
2001-11-06 |
2005-11-23 |
兰贝克赛实验室有限公司 |
甲福明控释片剂
|
US6667054B2
(en)
*
|
2001-12-05 |
2003-12-23 |
Bernard Charles Sherman |
Metformin hydrochloride tablets
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US8323692B2
(en)
|
2002-02-21 |
2012-12-04 |
Valeant International Bermuda |
Controlled release dosage forms
|
US8128957B1
(en)
|
2002-02-21 |
2012-03-06 |
Valeant International (Barbados) Srl |
Modified release compositions of at least one form of tramadol
|
US20050182056A9
(en)
*
|
2002-02-21 |
2005-08-18 |
Seth Pawan |
Modified release formulations of at least one form of tramadol
|
WO2003080031A1
(en)
*
|
2002-03-22 |
2003-10-02 |
Cilag Ag |
Sustained release formulation of tramadol
|
EP1492511B3
(de)
|
2002-04-09 |
2012-05-02 |
Flamel Technologies |
Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
|
US20040052848A1
(en)
*
|
2002-05-23 |
2004-03-18 |
Xiu-Xiu Cheng |
Biguanide formulations
|
WO2003105809A1
(en)
|
2002-06-17 |
2003-12-24 |
Themis Laboratories Private Limited |
Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
GB0214013D0
(en)
*
|
2002-06-18 |
2002-07-31 |
Euro Celtique Sa |
Pharmaceutical product
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
PA8578501A1
(es)
*
|
2002-07-25 |
2005-02-04 |
Pharmacia Corp |
Forma de dosificacion una vez al dia de pramipexol
|
WO2004012715A1
(en)
*
|
2002-08-02 |
2004-02-12 |
Penwest Pharmaceuticals Company |
Sustained release formulations of metformin
|
US8268352B2
(en)
*
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
US8216609B2
(en)
*
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
EP1545453B1
(de)
*
|
2002-08-29 |
2009-11-18 |
ActivBiotics Pharma LLC |
Rifalazil zur behandlung von infektionen mit clostridium difficile
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US9060941B2
(en)
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
JP2006506362A
(ja)
*
|
2002-10-11 |
2006-02-23 |
デポメド・ディベロップメント・リミテッド |
胃内保持型レボドパデリバリー形態
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
US20040131672A1
(en)
*
|
2003-01-07 |
2004-07-08 |
Nilobon Podhipleux |
Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
|
US20040147509A1
(en)
|
2003-01-13 |
2004-07-29 |
Dynogen Pharmaceuticals, Inc. |
Method of treating functional bowel disorders
|
MXPA05009886A
(es)
*
|
2003-03-14 |
2006-05-04 |
Nirmal Mulye |
Un proceso para preparar tabletas de liberacion constante.
|
WO2004087175A1
(en)
*
|
2003-04-04 |
2004-10-14 |
Pharmacia Corporation |
Oral extended release compressed tablets of multiparticulates
|
AU2004249211A1
(en)
*
|
2003-06-16 |
2004-12-29 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
US20050013863A1
(en)
*
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
US8313776B2
(en)
*
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
US8313775B2
(en)
*
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
WO2005009364A2
(en)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
DE10361596A1
(de)
*
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
ATE454138T1
(de)
*
|
2003-08-08 |
2010-01-15 |
Biovail Lab Int Srl |
Tablette mit modifizierter freisetzung von bupropion hydrochlorid
|
EP1653925A1
(de)
*
|
2003-08-11 |
2006-05-10 |
Advancis Pharmaceutical Corporation |
Robustes pellet
|
CA2535398C
(en)
*
|
2003-08-12 |
2013-11-12 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
EP1510208A1
(de)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
|
JP5686494B2
(ja)
*
|
2003-08-29 |
2015-03-18 |
シオノギ インコーポレイテッド |
抗生物質製剤、その使用法及び作成方法
|
JP2007513869A
(ja)
*
|
2003-09-15 |
2007-05-31 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
EP1680098A4
(de)
*
|
2003-11-04 |
2012-06-13 |
Supernus Pharmaceuticals Inc |
Verzögerte freisetzung von positiv geladenen pharmakologisch wirksamen molekülen aus einer polymer-haltigen matrix mit polarisierten sauerstoffatomen
|
US20050142187A1
(en)
*
|
2003-12-24 |
2005-06-30 |
Treacy Donald J.Jr. |
Enhanced absorption of modified release dosage forms
|
US20070196396A1
(en)
*
|
2004-02-11 |
2007-08-23 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
EP1591114A1
(de)
*
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Verwendung von Metformin und Orlistat zur Behandlung oder Vorbeugung von Obesität
|
KR100772980B1
(ko)
*
|
2004-04-01 |
2007-11-02 |
한미약품 주식회사 |
메트포르민의 경구투여용 서방성 제제
|
MXPA06014587A
(es)
|
2004-06-17 |
2007-04-27 |
Forest Laboratories |
Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US8715727B2
(en)
*
|
2004-07-02 |
2014-05-06 |
Shionogi Inc. |
Tablet for pulsed delivery
|
RS51527B2
(sr)
*
|
2004-08-13 |
2018-02-28 |
Boehringer Ingelheim Int |
Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
|
CN101849920A
(zh)
*
|
2004-08-13 |
2010-10-06 |
贝林格尔·英格海姆国际有限公司 |
包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
|
CA2580329C
(en)
|
2004-09-13 |
2015-01-06 |
Chrono Therapeutics Inc. |
Biosynchronous transdermal drug delivery
|
KR100760430B1
(ko)
*
|
2004-12-31 |
2007-10-04 |
한미약품 주식회사 |
당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
|
DE102005005449A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8968781B2
(en)
*
|
2005-04-29 |
2015-03-03 |
Cubist Pharmaceuticals, Inc. |
Therapeutic compositions
|
US7541347B2
(en)
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
US7544373B2
(en)
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US20080242642A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7919483B2
(en)
*
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
US20080241235A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
US7884136B2
(en)
|
2005-06-27 |
2011-02-08 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
PL1919466T3
(pl)
|
2005-07-11 |
2012-05-31 |
Cortria Corp |
Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
WO2007020508A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Ferring International Center S.A. |
Method and device for dividing granules
|
CA2620370A1
(en)
*
|
2005-08-30 |
2007-03-22 |
Nicholas Piramal India Limited |
Extended release pharmaceutical composition of metformin and a process for producing it
|
EP1954257A4
(de)
|
2005-10-14 |
2009-05-20 |
Lundbeck & Co As H |
Verfahren zur behandlung von erkrankungen des zentralen nervensystems mit einer niedrigdosierten kombination aus escitalopram und bupropion
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
WO2007090883A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Extended release formulation
|
JP2009526021A
(ja)
*
|
2006-02-10 |
2009-07-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
放出を加減した製剤
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
ES2572180T3
(es)
*
|
2006-04-26 |
2016-05-30 |
Alphapharm Pty Ltd |
Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
|
AU2013202441B2
(en)
*
|
2006-04-26 |
2016-02-25 |
Alphapharm Pty Ltd |
Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
WO2008084698A1
(ja)
|
2006-12-28 |
2008-07-17 |
Astellas Pharma Inc. |
タクロリムス徐放性医薬組成物
|
CN105152983A
(zh)
|
2007-01-29 |
2015-12-16 |
韩诺生物制药株式会社 |
N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
|
DE102007011485A1
(de)
*
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
CA2682661C
(en)
|
2007-03-22 |
2017-03-14 |
Dendreon Corporation |
Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
|
US20080241197A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline dosage forms for the treatment of acne
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
WO2009004592A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Wockhardt Research Centre |
Vancomycin compositions
|
JP5651818B2
(ja)
|
2007-12-17 |
2015-01-14 |
パラディン ラブス インコーポレーテッド |
誤用を防止するための放出制御製剤
|
EP2249811A1
(de)
*
|
2008-01-25 |
2010-11-17 |
Grünenthal GmbH |
Pharmazeutische dosierform
|
US20090246276A1
(en)
*
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
US20100330177A1
(en)
*
|
2008-02-05 |
2010-12-30 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
AU2009220444A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
|
WO2009114648A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Depomed Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
JP5114281B2
(ja)
*
|
2008-04-17 |
2013-01-09 |
塩野義製薬株式会社 |
塩酸バンコマイシンを含有する錠剤
|
HUE030803T2
(en)
*
|
2008-05-09 |
2017-06-28 |
Gruenenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
|
CN103479586B
(zh)
|
2008-05-15 |
2017-03-01 |
细胞基因公司 |
胞苷类似物的口服制剂和其使用方法
|
ZA200903854B
(en)
*
|
2008-06-19 |
2011-02-23 |
Univ Of The Witwatesrand Johannesburg |
A gastroretentive pharmaceutical dosage form
|
US20100003322A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Lai Felix S |
Enteric coated hydrophobic matrix formulation
|
WO2010017310A1
(en)
|
2008-08-06 |
2010-02-11 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
WO2010026467A2
(en)
|
2008-09-04 |
2010-03-11 |
Torrent Pharmaceuticals Ltd. |
Controlled release dosage form of high solubility active ingredient
|
CA2737257C
(en)
|
2008-09-18 |
2016-11-15 |
Purdue Pharma L.P. |
Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
|
WO2010038237A2
(en)
|
2008-09-22 |
2010-04-08 |
Rubicon Research Private Limited |
Compositions exhibiting delayed transit through the gastrointestinal tract
|
AU2009301994B2
(en)
|
2008-10-08 |
2016-10-20 |
Bioplus Life Sciences Pvt. Ltd. |
Sustained release drug delivery system
|
US8486449B2
(en)
|
2008-12-16 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
EP2421524B1
(de)
|
2009-04-20 |
2018-08-08 |
Elcelyx Therapeutics, Inc. |
Auf chemosensorischen rezeptorliganden basierende therapien
|
US8828953B2
(en)
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
EP3195896A1
(de)
|
2009-05-05 |
2017-07-26 |
Board of Regents, The University of Texas System |
Neue formulierungen flüchtiger anästhetika und anwendungsverfahren zur entzündungslinderung
|
EP2456427B1
(de)
|
2009-07-22 |
2015-03-04 |
Grünenthal GmbH |
Heißschmelzextrudierte retardierte pharmazeutische Darreichungsform
|
PE20120572A1
(es)
|
2009-07-22 |
2012-06-06 |
Gruenenthal Chemie |
Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
|
US20110052700A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
|
AU2010286354A1
(en)
*
|
2009-08-31 |
2012-04-19 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
|
US20110104273A1
(en)
*
|
2009-11-05 |
2011-05-05 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
|
US20110135728A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Miller Jennifer L |
Gastric retentive pharmaceutical compositions for extended release of polypeptides
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
EP2531176B1
(de)
*
|
2010-02-03 |
2016-09-07 |
Grünenthal GmbH |
Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels eines extruders
|
JP2010120967A
(ja)
*
|
2010-02-24 |
2010-06-03 |
Shionogi & Co Ltd |
塩酸バンコマイシンを含有する錠剤
|
TR201802207T4
(tr)
|
2010-03-29 |
2018-03-21 |
Astellas Pharma Inc |
Kontrollü Salımlı Farmasötik Bileşim.
|
WO2011125798A1
(ja)
*
|
2010-03-31 |
2011-10-13 |
持田製薬株式会社 |
易服用性固形製剤
|
US8581001B2
(en)
|
2010-04-16 |
2013-11-12 |
Codman & Shurtleff |
Metformin-cysteine prodrug
|
AU2011289407B2
(en)
|
2010-08-11 |
2015-06-18 |
Philadelphia Health & Education Corporation |
Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
|
PE20131126A1
(es)
|
2010-09-02 |
2013-10-21 |
Gruenenthal Chemie |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico
|
NZ607392A
(en)
|
2010-09-02 |
2015-03-27 |
Gruenenthal Chemie |
Tamper resistant dosage form comprising inorganic salt
|
MX346203B
(es)
|
2010-09-28 |
2017-03-09 |
Depomed Inc |
Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
|
EP2630491A4
(de)
|
2010-10-19 |
2014-08-27 |
Elcelyx Therapeutics Inc |
Auf chemosensorischen rezeptorliganden basierende therapien
|
ES2687027T3
(es)
|
2010-11-08 |
2018-10-23 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepáticas
|
US8435993B2
(en)
|
2010-12-07 |
2013-05-07 |
Philadelphia Health And Education Corporation |
Methods of inhibiting metastasis from cancer
|
DK2661266T3
(da)
|
2011-01-07 |
2020-11-16 |
Anji Pharma Us Llc |
Kemosensoriske receptorligandbaserede terapier
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US9119793B1
(en)
|
2011-06-28 |
2015-09-01 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for doxycycline
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
DK2736497T3
(da)
|
2011-07-29 |
2017-11-13 |
Gruenenthal Gmbh |
Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
|
EP2736495B1
(de)
|
2011-07-29 |
2017-08-23 |
Grünenthal GmbH |
Verfälschungssichere multipartikular-tablette, die eine sofortige wirkstofffreigabe bereitstellt
|
CN107049979B
(zh)
|
2011-09-30 |
2020-08-14 |
持田制药株式会社 |
易服用性固体制剂
|
KR20140088603A
(ko)
|
2011-11-01 |
2014-07-10 |
셀진 코포레이션 |
시티딘 유사체의 경구 제제를 사용하여 암을 치료하는 방법
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
KR101939710B1
(ko)
|
2011-12-21 |
2019-01-17 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
LT2838512T
(lt)
|
2012-04-18 |
2018-11-12 |
GrĆ¼nenthal GmbH |
Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
EP2874997A4
(de)
|
2012-07-19 |
2016-01-06 |
Univ Drexel |
Neue sigma-rezeptorliganden und verfahren zur regulierung der zellulären proteinhomöostase damit
|
EP3158995B1
(de)
|
2012-08-09 |
2018-05-23 |
Dynamis Therapeutics, Inc. |
Meglumin zur absenkung eines hohen triglyceridspiegels
|
US20140150787A1
(en)
*
|
2012-12-04 |
2014-06-05 |
Civitas Therapeutics, Inc. |
Devices and methods for puncturing a capsule to release a powdered medicament therefrom
|
EP2941233B1
(de)
|
2013-01-07 |
2020-10-07 |
The Trustees of the University of Pennsylvania |
Zusammensetzungen und verfahren zur behandlung von t-zelllymphom
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
US10842802B2
(en)
|
2013-03-15 |
2020-11-24 |
Medicis Pharmaceutical Corporation |
Controlled release pharmaceutical dosage forms
|
US20150374688A1
(en)
|
2013-03-26 |
2015-12-31 |
Wockhardt Limited |
Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof.
|
WO2014170770A1
(en)
|
2013-03-28 |
2014-10-23 |
Wockhardt Limited |
Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
US10154966B2
(en)
|
2013-05-29 |
2018-12-18 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
US10166207B2
(en)
|
2013-06-05 |
2019-01-01 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
AU2014284267B2
(en)
|
2013-07-02 |
2018-05-10 |
Ecoplanet Environmental Llc |
Volatile organic compound formulations having antimicrobial activity
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
KR20160031526A
(ko)
|
2013-07-12 |
2016-03-22 |
그뤼넨탈 게엠베하 |
에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
|
KR101597004B1
(ko)
|
2013-07-25 |
2016-02-23 |
씨제이헬스케어 주식회사 |
서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
|
CA2931553C
(en)
|
2013-11-26 |
2022-01-18 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
EP3074049B1
(de)
|
2013-11-26 |
2020-05-06 |
Yale University |
Neuartige zellenpenetrierende zusammensetzungen und verfahren zur verwendung davon
|
EP3079692A4
(de)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Neuartiges verfahren zur behandlung einer neurodegenerativen krankheit bei einem säugetier mit derartigem bedarf
|
CA2982270C
(en)
|
2014-04-07 |
2023-01-10 |
Women & Infants Hospital Of Rhode Island |
Novel 7-dehydrocholesterol derivatives and methods using same
|
EP3142646A1
(de)
|
2014-05-12 |
2017-03-22 |
Grünenthal GmbH |
Manipulationssichere kapselformulierung mit tapentadol mit unmittelbarer freisetzung
|
US9872835B2
(en)
|
2014-05-26 |
2018-01-23 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
WO2015199146A1
(ja)
*
|
2014-06-25 |
2015-12-30 |
味の素株式会社 |
固形製剤及びその安定化方法
|
CA2952406A1
(en)
|
2014-06-25 |
2015-12-30 |
Ea Pharma Co., Ltd. |
Solid formulation and method for preventing or reducing coloration thereof
|
CA2968215A1
(en)
|
2014-08-20 |
2016-02-25 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
WO2016029004A1
(en)
|
2014-08-22 |
2016-02-25 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
AU2016211330A1
(en)
|
2015-01-28 |
2017-08-03 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
US9579289B2
(en)
|
2015-02-20 |
2017-02-28 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form
|
US10172800B2
(en)
|
2015-02-20 |
2019-01-08 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form with enhanced pharmacokinetics
|
US10987328B2
(en)
|
2015-02-20 |
2021-04-27 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form
|
US10300032B2
(en)
|
2015-02-20 |
2019-05-28 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
AU2016264364B2
(en)
|
2015-05-19 |
2022-06-23 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
KR102207539B1
(ko)
|
2015-06-30 |
2021-01-26 |
네우라드 리미티드 |
신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
|
WO2017042325A1
(en)
|
2015-09-10 |
2017-03-16 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
KR20180063125A
(ko)
|
2015-10-15 |
2018-06-11 |
아지오스 파마슈티컬스 아이엔씨. |
악성종양을 치료하기 위한 복합 요법
|
US10695352B2
(en)
|
2015-10-15 |
2020-06-30 |
Celgene Corporation |
Combination therapy for treating malignancies
|
BR112018007656A2
(pt)
|
2015-10-15 |
2018-11-06 |
Agios Pharmaceuticals Inc |
terapia de combinação para tratamento de doenças malignas
|
EP3368505B1
(de)
|
2015-10-28 |
2023-02-22 |
Yale University |
Chinolinamide und verfahren zur verwendung davon
|
CA3005142A1
(en)
|
2015-11-20 |
2017-05-26 |
Yale University |
Compositions for treating ectopic calcification disorders, and methods using same
|
KR20180086255A
(ko)
|
2015-12-04 |
2018-07-30 |
아지오스 파마슈티컬스 아이엔씨. |
악성종양의 치료 방법
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
WO2017146794A1
(en)
|
2016-02-26 |
2017-08-31 |
Celgene Corporation |
Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
|
JP7418958B2
(ja)
|
2016-03-17 |
2024-01-22 |
チオジェネシス セラピューティクス, インコーポレイテッド |
システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US10143687B2
(en)
|
2016-04-11 |
2018-12-04 |
Neurocea, LLC |
Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
|
US10292977B2
(en)
|
2016-04-11 |
2019-05-21 |
Neurocea, LLC |
Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
|
CA3017444A1
(en)
*
|
2016-04-23 |
2017-10-26 |
Jayendrakumar Dasharathlal PATEL |
Tamper resistant pharmaceutical composition
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
WO2018026764A1
(en)
|
2016-08-01 |
2018-02-08 |
University Of Rochester |
Nanoparticles for controlled release of anti-biofilm agents and methods of use
|
EP3493809B1
(de)
|
2016-08-03 |
2023-08-23 |
Celgene Corporation |
Enasidenib zur behandlung von myelodysplastischem syndrom
|
WO2018027024A1
(en)
|
2016-08-05 |
2018-02-08 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
CN109843379B
(zh)
|
2016-09-01 |
2022-12-30 |
梅比斯发现公司 |
取代脲及其制备和使用方法
|
CA3040919A1
(en)
|
2016-11-07 |
2018-05-11 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
JP2020503950A
(ja)
|
2017-01-06 |
2020-02-06 |
クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. |
経皮薬剤送達の装置及び方法
|
EP4219486A1
(de)
|
2017-01-19 |
2023-08-02 |
Temple University of the Commonwealth System of Higher Education |
Verbrückte bicycloalkyl-substituierte aminothizole und verfahren zu ihrer verwendung
|
US11098010B2
(en)
|
2017-03-21 |
2021-08-24 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
EP3612184A4
(de)
|
2017-04-17 |
2021-01-20 |
Yale University |
Verbindungen, zusammensetzungen und verfahren zur behandlung oder prävention von akuten lungenverletzungen
|
US11229653B2
(en)
|
2017-05-05 |
2022-01-25 |
Celgene Corporation |
Methods of treatment of myeloproliferative neoplasm
|
US10987311B2
(en)
|
2017-06-16 |
2021-04-27 |
Kashiv Specialty Pharmaceuticals, Llc |
Extended release compositions comprising pyridostigmine
|
US10588863B2
(en)
|
2017-06-16 |
2020-03-17 |
Kashiv Biosciences, Llc |
Extended release compositions comprising pyridostigmine
|
ES2928071T3
(es)
|
2017-06-16 |
2022-11-15 |
Amneal Complex Products Res Llc |
Formas de dosificación gastrorretentiva para el suministro sostenido de fármacos
|
JP6854384B2
(ja)
|
2017-07-17 |
2021-04-07 |
イーライ リリー アンド カンパニー |
医薬組成物
|
WO2019018158A1
(en)
|
2017-07-17 |
2019-01-24 |
Eli Lilly And Company |
PHARMACEUTICAL COMPOSITIONS
|
EP3659307A4
(de)
|
2017-07-28 |
2021-09-22 |
Yale University |
Antikrebsmittel und verfahren zur herstellung und verwendung davon
|
WO2019032026A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
|
CA3074017A1
(en)
|
2017-09-08 |
2019-03-14 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
|
CN111683684A
(zh)
|
2017-09-20 |
2020-09-18 |
硫创治疗公司 |
用于治疗半胱胺敏感性病症的方法
|
WO2019087084A1
(en)
|
2017-11-02 |
2019-05-09 |
Eman Biodiscoveries Sd. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
WO2019104316A1
(en)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
EP3737353A1
(de)
|
2017-12-18 |
2020-11-18 |
Tris Pharma, Inc. |
Pharmazeutische ghb-zusammensetzungen mit einem system zur formung von schwimmenden interpenetrierenden polymernetzwerken
|
WO2019126218A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
US11325920B2
(en)
|
2018-01-24 |
2022-05-10 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
KR20200116110A
(ko)
|
2018-01-29 |
2020-10-08 |
듀크 유니버시티 |
5-히드록시트립토판 생체이용률을 높이는 조성물 및 방법
|
AU2019279884A1
(en)
|
2018-05-29 |
2020-12-10 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|
CN112204025B
(zh)
|
2018-05-29 |
2022-05-31 |
瑟赛治疗公司 |
用于治疗疼痛的化合物,包含其的组合物以及使用其的方法
|
JP7391048B2
(ja)
|
2018-06-05 |
2023-12-04 |
アルビレオ・アクチボラグ |
ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
DK3824881T3
(da)
|
2018-06-18 |
2022-05-09 |
Amneal Complex Products Res Llc |
Sammensætning omfattende pyridostigminbromid med forlænget frigivelse
|
CA3103477A1
(en)
|
2018-06-19 |
2019-12-26 |
National University Of Singapore |
Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
CA3100687A1
(en)
|
2018-06-20 |
2019-12-26 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
CN112839661A
(zh)
|
2018-10-11 |
2021-05-25 |
萨尼菲特治疗有限公司 |
用于治疗异位钙化的肌醇磷酸酯类
|
US20210403452A1
(en)
|
2018-11-02 |
2021-12-30 |
Celgene Corporation |
Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
|
WO2020092915A1
(en)
*
|
2018-11-02 |
2020-05-07 |
Celgene Corporation |
Solid dispersions for treatment of cancer
|
WO2020092906A1
(en)
|
2018-11-02 |
2020-05-07 |
Celgene Corporation |
Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
CN113365636A
(zh)
|
2019-01-30 |
2021-09-07 |
萨尼菲特治疗有限公司 |
用于增加组织灌注的磷酸肌醇化合物
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
KR102186704B1
(ko)
*
|
2019-02-18 |
2020-12-04 |
(주)아이엠디팜 |
서방성 지질 전구 제제 및 이를 포함하는 지질 용액 형태의 서방성 주사용 약학 조성물
|
US11524048B2
(en)
|
2019-05-09 |
2022-12-13 |
The Feinstein Institutes For Medical Research |
HMGB1 antagonist treatment of severe sepsis
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
EP3818983A1
(de)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
|
EP4069247A1
(de)
|
2019-12-04 |
2022-10-12 |
Albireo AB |
Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren
|
DK4069360T3
(da)
|
2019-12-04 |
2024-02-26 |
Albireo Ab |
Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
|
EP4069359B1
(de)
|
2019-12-04 |
2024-01-03 |
Albireo AB |
Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
|
EP4069361B1
(de)
|
2019-12-04 |
2024-01-03 |
Albireo AB |
Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
IL298853A
(en)
|
2020-06-09 |
2023-02-01 |
Inozyme Pharma Inc |
Soluble ENPP1 or ENPP3 proteins and their uses
|
EP4188541A1
(de)
|
2020-08-03 |
2023-06-07 |
Albireo AB |
Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren
|
JP2023549226A
(ja)
|
2020-11-12 |
2023-11-22 |
アルビレオ エービー |
進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
|
AU2021390172A1
(en)
|
2020-12-04 |
2023-06-22 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
EP4015494A1
(de)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Verfahren zur herstellung von löslichen salzen von inositolphosphaten
|
EP4036097A1
(de)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6-substituierte derivatverbindungen
|
CA3226223A1
(en)
|
2021-07-30 |
2023-02-02 |
Jacob Pade Ramsoe Jacobsen |
5-hydroxytryptophan gastroretentive dosage forms
|
US11779567B2
(en)
|
2021-10-14 |
2023-10-10 |
Evecxia Therapeutics, Inc. |
Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
WO2024023359A1
(en)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
WO2024023360A1
(en)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Ip5 substituted compounds
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|